How is LL-37 dosed and mixed?
250 mcg of LL-37 from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 5 mg | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units | 2.5 mg/mL: 250 mcg is 10 units, 500 mcg is 20 units |
| 10 mg | 10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units |
In the phase IIb HEAL LL-37 trial (Mahlapuu et al., 2021) of 148 patients with hard-to-heal venous leg ulcers, LL-37 at 0.5 or 1.6 mg/mL was applied to the wound bed twice weekly against placebo,1 and searches of DailyMed, PubMed and ClinicalTrials.gov found no LL-37 label or approved dose.
Mixing arithmetic for an LL-37 vial
250 mcg of LL-37 from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
250 mcg of LL-37 from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
Searches of DailyMed, PubMed and ClinicalTrials.gov found no label or maker's leaflet with an LL-37 vial strength, water type or water volume. The vial sizes and water volumes in the table are arithmetic only, shown for the 250 and 500 µg per-tumour doses that the melanoma registry entry gives for once-a-week injections into tumours; the entry gives no vial strength, water or injection volume.2
Doses and schedules in LL-37 trials
Searches of DailyMed, PubMed and ClinicalTrials.gov found no LL-37 label and no approved dose. The trials below applied LL-37 to ulcers or injected it into melanoma tumours.1342
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Grönberg et al., 2014, first-in-man, on venous leg ulcers | Topical, twice weekly at 0.5, 1.6 or 3.2 mg/mL, against placebo4 | 34 | 4 weeks |
| Mahlapuu et al., 2021 (HEAL LL-37), on the wound bed of venous leg ulcers | 0.5 or 1.6 mg/mL at 25 μL per cm2 (12.5 or 40 μg/cm2), twice weekly, against placebo1 | 148 (149 recruited, per the methods)1 | 13 weeks |
| Miranda et al., 2023, cream on diabetic foot ulcers in Indonesia5 | 0.5 mg/g cream, 0.025 mL per cm2, twice a week, against placebo cream3 | 25 (13 LL-37, 12 placebo)3 | 4 weeks |
| NCT02225366 (M.D. Anderson Cancer Center), injections into melanoma tumours | Once a week per tumour: 250 µg in the first cohort, 500 µg in the second2 | 4 enrolled; planned up to 2 per dose level, up to 4 levels2 | 8 weeks |
An open-label, randomized trial (Zhao et al., 2023) of 238 adult inpatients with COVID-19 compared a recombinant Lactococcus lactis product (Oral LL-37) with placebo, and its published summary gives no mg dose.6 No human trial of a subcutaneous injection of LL-37 turned up in the registry or PubMed searches. None of the trials or registry entries above gives on and off cycles; each gives a fixed treatment length.
What is known about LL-37 storage
Searches found no storage condition for LL-37 powder or for a mixed solution. The only stability data the searches found are for the Miranda et al. trial's cream: in a 12-week accelerated stability test, the LL-37 cream in jars melted at 40 °C while remaining stable at 4 °C and 28 °C, and the paper says it could be stored at 4 °C for 99 months with more than 90% of the active ingredient; none of this concerns a mixed injection.3 A review of cathelicidins says maintaining the stability of LL-37 in biological environments remains a significant issue, as cathelicidins are susceptible to proteolytic cleavage and unstable under high salt concentrations; it gives no storage conditions for a vial.7 It also lists rapid enzymatic degradation and a short plasma half-life among the critical challenges to the clinical application of LL-37.7
Frequently asked questions
What does FDA say about compounded LL-37?
On a page current as of 04/22/2026, FDA lists cathelicidin LL-37 among bulk drug substances previously in category 2 that were withdrawn by the nominators, and says compounded drugs containing it may pose risk for immunogenicity for certain routes of administration and that FDA lacks sufficient safety-related information to know whether it would cause harm when administered to humans.8 FDA adds that nonclinical research findings suggest detrimental effects on male reproduction and that LL-37 can be protumorigenic in some tissues.8
What side effects did LL-37 trials report?
In the phase IIb trial, 12 non-fatal serious adverse events occurred in 11 patients, none assessed as related to the study drug, and there were no deaths.1 In the same trial, at least one adverse event was reported by 20 of 48 patients on 0.5 mg/mL, 24 of 49 on 1.6 mg/mL and 20 of 51 on placebo.1 A 2018 case report (Dolkar et al.) describes dermatologic toxicity in a 63-year-old woman with stage IIIC melanoma who received a total of 8 weekly LL-37 injections, with skin lesions appearing approximately 45 days after the therapy began.9 The authors of the 2014 first-in-man trial report no safety concerns regarding local or systemic adverse events,4 and the oral trial's published summary says no severe adverse events were observed during hospitalization and follow-up.6
Is there a registered trial of LL-37, and what dose does it list?
Of the studies a ClinicalTrials.gov search for LL-37 returned, two list LL-37 as the treatment. NCT02225366 is an M.D. Anderson melanoma study with a starting dose of 250 µg per tumour and 4 people enrolled.2 NCT04098562 lists 0.5 mg/mL cream twice a week for 4 weeks, planned for 40 patients against placebo cream.5 The registry entry cites the Miranda et al. trial as its publication.5 That published trial reports 25 participants and gives the cream as 0.5 mg/g.3
References
- Wiley / PMC. Evaluation of LL‐37 in healing of hard‐to‐heal venous leg ulcers: A multicentric prospective randomized placebo‐controlled clinical trial. 2021. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT02225366: Intratumoral Injections of LL37 for Melanoma. 2021. clinicaltrials.gov
- Wiley / PMC. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. 2023. pmc.ncbi.nlm.nih.gov
- PubMed. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. 2014. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT04098562: Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers. 2020. clinicaltrials.gov
- PubMed. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. 2023. pubmed.ncbi.nlm.nih.gov
- Int J Mol Sci / PMC. Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications. 2025. pmc.ncbi.nlm.nih.gov
- FDA. Substances in Compounding that May Present Significant Safety Risks. fda.gov
- PubMed. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. 2018. pubmed.ncbi.nlm.nih.gov